Trial Profile
A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Namilumab/MT203 at 4 Different Subcutaneous Doses - Together With an Open-Label, Dose-Escalated Extension to Assess Safety and Efficacy of One Year Treatment - in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Namilumab (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms Neptune
- Sponsors Takeda
- 12 Sep 2018 Results investigating clinical use of GM-CSF neutralisation by evaluating efficacy and safety of namilumab published in the British Journal of Dermatology
- 12 Oct 2016 Trial has been completed in Latvia (end date: 2016-02-23)
- 01 Jul 2015 No. of arms changed from 5 to 7 with change in time frame as per ClinicalTrials.gov record